Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID).

Autor: Williams LA; Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, Texas, 77030, USA. loriwilliams@mdanderson.org., Whisenant MS; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1330, Houston, TX, 77030, USA., Mendoza TR; Office of Patient-Centered Research Outcomes, Center for Cancer Research, National Cancer Institute, Bldg. 82, Rm. B03A, Bethesda, MD, 20892, USA., Peek AE; Department of Electronic Health Record Ambulatory Access & Revenue, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1746, Houston, TX, 77030, USA., Malveaux D; Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, Texas, 77030, USA., Griffin DK; Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, Texas, 77030, USA., Ponce DA; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1330, Houston, TX, 77030, USA., Granwehr BP; Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0402, Houston, TX, 77030, USA., Sheshadri A; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1462, Houston, TX, 77030, USA., Hutcheson KA; Department of Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1445, Houston, TX, 77030, USA., Ali SM; Department of Electronic Health Record Analytics & Reporting, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1747, Houston, TX, 77030, USA., Peterson SK; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1330, Houston, TX, 77030, USA., Heymach JV; Department of Thoracic-Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0432, Houston, TX, 77030, USA., Cleeland CS; Symptom Assessment Systems LLC, 1416 Marconi St., Houston, TX, 77019, USA., Subbiah IM; Sarah Cannon Research Institute, 1100 Dr. Martin L. King Jr. Blvd., Suite 800, Nashville, TN, 37203, USA.
Jazyk: angličtina
Zdroj: Journal of patient-reported outcomes [J Patient Rep Outcomes] 2023 May 26; Vol. 7 (1), pp. 48. Date of Electronic Publication: 2023 May 26.
DOI: 10.1186/s41687-023-00591-x
Abstrakt: Background: Symptom expression in SARS-CoV-2 infection (COVID-19) may affect patients already symptomatic with cancer. Patient-reported outcomes (PROs) can describe symptom burden during the acute and postacute stages of COVID-19 and support risk stratification for levels of care. At the start of the COVID-19 pandemic, our purpose was to rapidly develop, launch through an electronic patient portal, and provide initial validation for a PRO measure of COVID-19 symptom burden in patients with cancer.
Methods: We conducted a CDC/WHO web-based scan for COVID-19 symptoms and a relevance review of symptoms by an expert panel of clinicians treating cancer patients with COVID-19 to create a provisional MD Anderson Symptom Inventory for COVID-19 (MDASI-COVID). English-speaking adults with cancer who tested positive for COVID-19 participated in the psychometric testing phase. Patients completed longitudinal assessments of the MDASI-COVID and the EuroQOL 5 Dimensions 5 Levels (EQ-5D-5L) utility index and visual analog scale, which were presented through an electronic health record patient portal. To test the validity of the MDASI-COVID to distinguish between known groups of patients, we hypothesized that patients hospitalized, including having a hospitalization extended, for COVID-19 versus those not hospitalized would experience higher symptom burden. Correlation of mean symptom severity and interference scores with relevant EQ-5D-5L scores tested concurrent validity. The reliability of the MDASI-COVID was evaluated by calculating Cronbach alpha coefficients and test-retest reliability was evaluated by calculating Pearson correlation coefficients between the initial assessment and a second assessment no more than 14 days later.
Results: The web-based scan found 31 COVID-19-related symptoms; rankings of a 14-clinician expert panel reduced this list to 11 COVID-specific items to be added to the core MDASI. Time from literature scan start in March 2020 to instrument launch in May 2020 was 2 months. Psychometric analysis established the MDASI-COVID's reliability, known-group validity, and concurrent validity.
Conclusions: We were able to rapidly develop and electronically launch a PRO measure of COVID-19 symptom burden in patients with cancer. Additional research is needed to confirm the content domain and predictive validity of the MDASI-COVID and define the symptom burden trajectory of COVID-19.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: